Oncorus Inc   (ONCR)
Other Ticker:  
Price: $0.1260 $0.00 -3.077%
Day's High: $0.2 Week Perf: 869.23 %
Day's Low: $ 0.13 30 Day Perf: 193.02 %
Volume (M): 136 52 Wk High: $ 0.43
Volume (M$): $ 17 52 Wk Avg: $0.14
Open: $0.13 52 Wk Low: $0.01

 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 26
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -91
 Cash Flow (TTM) (Millions $) -54
 Capital Exp. (TTM) (Millions $) 18

Oncorus Inc
Oncorus Inc is a biotechnology company dedicated to the development of innovative immunotherapies for the treatment of various types of cancers. The company focuses on developing viral-based therapies that can selectively infect and destroy cancer cells while leaving healthy cells intact. Oncorus uses a proprietary therapeutic platform called Synthetic Virus, which enables the design and production of potent viral vectors for therapeutic purposes. These viral vectors can deliver therapeutic payloads directly to cancer cells, enhancing the immune response and potentially improving patient outcomes. The company's mission is to improve the lives of cancer patients and advance the field of immuno-oncology through their innovative approaches.

   Company Address: 4 Corporate Drive Andover 1810 MA
   Company Phone Number: 320-6400   Stock Exchange / Ticker: NASDAQ ONCR
   ONCR is expected to report next financial results on March 23, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Aclaris Therapeutics Inc

2. Aclaris Therapeutics Inc: Paving the Way for Innovative Healthcare Solutions

The strategic business review initiated by Aclaris Therapeutics aims to identify areas of improvement and optimize its resources to drive growth and create value for shareholders. The company is focused on leveraging its expertise in developing drug candidates for immuno-inflammatory diseases to capitalize on emerging opportunities in the healthcare market. With a strong pipeline of innovative products, Aclaris Therapeutics is well-positioned to address unmet medical needs and enhance patient outcomes.
Despite the recent financial challenges, Aclaris Therapeutics remains committed to advancing its mission of delivering groundbreaking therapies to patients in need. The company's dedication to research and development underscores its long-term vision for sustainable growth and success in the pharmaceutical industry. By investing in innovative healthcare solutions, Aclaris Therapeutics aims to expand its market presence and solidify its reputation as a leading provider of pharmaceutical preparations.

Esperion Therapeutics Inc

An ordinary revenue helped to reduce losess, at ESPR in the fiscal three months closing Dec 31 2023

As a financial journalist for the , I have been closely monitoring the recent financial results of Esperion Therapeutics Inc, a major player in the pharmaceutical industry. The company's fiscal three months ending December 31, 2023, showed a remarkable revenue growth of 71.378% to $32.25 million, leading to a decrease in losses to $-0.36 per share from $-0.48 in the previous year. Despite a slight decrease in revenue in the third quarter, the company managed to improve its earnings per share (EPS) from $-0.37 per share.
However, the fourth quarter of 2023 saw Esperion Therapeutics Inc facing a net shortfall of $-56.344 million, slightly higher than the previous year. The company also witnessed an increase in inventories and supplies, indicating a rise in demand. Accounts receivable also saw a noticeable increase, reaching $48.5 million, further highlighting the company's growth trajectory.

Zentalis Pharmaceuticals Inc

The Major Pharmaceutical Preparations company reported operating shortfall in the fourth quarter of 2023

The Major Pharmaceutical Preparations industry is currently facing significant challenges, as highlighted by the recent earnings report of Zentalis Pharmaceuticals Inc. These financial results have raised concerns among industry insiders and investors, indicating a bearish outlook for the company and potentially for the entire sector.
One alarming aspect of the earnings report is the operating shortfall of $-67.922 million observed by industry insiders. This shortfall indicates that Zentalis Pharmaceuticals Inc has not generated sufficient revenue to cover its operating expenses during the fourth quarter of 2023. Furthermore, the company has not mentioned any top-line figures, signaling a lack of growth and potential stagnation in its business performance.

Arcutis Biotherapeutics Inc

Strong 356.805%, gain in revenue , by Arcutis Biotherapeutics Inc in the financial three months ending December 31 2023

Arcutis Biotherapeutics Inc, a leading innovator in dermatology therapeutics, recently announced its financial results for the fourth quarter of 2023, showing significant improvements in various key metrics. The company's success can be attributed to its ongoing efforts to develop effective treatments for dermatological conditions, as demonstrated by the positive results from the pivotal Phase 3 STRATUM trial.
Financial Performance:
In the fourth quarter of 2023, Arcutis Biotherapeutics Inc saw a decrease in its loss per share, with $0.68 per share compared to $1.06 in the previous year. Furthermore, the company reported an increase in earnings per share from the previous reporting season, with $0.73 per share in contrast to the negative $0.73 per share previously.

Biomarin Pharmaceutical Inc

2 Subtitle options:Shareholders Disappointed as Biomarin Pharmaceutical Inc Reports Stagnant Earnings Despite Revenue Surge2.

Surge in Revenue Fails to Boost Earnings for Biomarin Pharmaceutical Inc in Q4 2023
Investors were taken by surprise as major pharmaceutical preparations company, Biomarin Pharmaceutical Inc (BMRN), reported stagnant earnings despite a substantial increase in revenue during the fourth quarter of the 2023 earnings season. Net profit per share remained unchanged at $0.11, marking a disappointment for shareholders.
BMRN's revenue, however, experienced a significant jump of 20.216% to $646.21 million compared to the same quarter in the previous year. This growth is noteworthy, especially considering the overall major pharmaceutical preparations sector experienced a decline of -15.67% in top-line revenue. Reflecting on the industry's performance, BMRN stands out with its revenue growth.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com